Large arrow graphic

On August 1st, inVentiv Health and INC Research became one company.
The result? Biopharmaceutical Acceleration.

It happens when clinical and commercial work hand in hand together. When the walls between disciplines come down and are replaced by the sharing of data and critical insights. When everyone in the company begins their work with the ultimate end in mind. Biopharmaceutical acceleration is a game changer and it’s happening here.

  • Average study start-up time four weeks faster than industry average.1
  • Database lock faster than industry average.1
  • Helped to develop or commercialize at least 82% of all Novel New Drugs approved by the FDA in a recent five-year period.
  • Helped develop or commercialize at least 70% of products granted marketing authorization by the EMA in a recent five-year period.

1Based on reported benchmarks from CMR International Institute for Regulatory Science

Learn More About INC Research/inVentiv Health

Investor Relations Contact

Ronnie Speight
Vice President, Investor Relations
+1 919 745 2745
Investor.Relations@incresearch.com

Press/Media Contact

Danielle DeForge
Senior Director, External Communications
+1 202 210 5992
Danielle.DeForge@inventivhealth.com

To learn more about how inVentiv Health experts can help you, please contact us by clicking here.

Contact Us


inVentiv Health has been made aware of an internet scam targeting job seekers who have posted their resumes on job posting websites. Scammers are contacting applicants via email and purporting to represent inVentiv Health. Many of these scammers are using Gmail accounts and Google Hangouts to communicate with applicants. All correspondence with us comes from an internal employee with a valid @inventivhealth.com email address. Anyone who suspects they have been solicited in this scam should contact the FBI at ic3.gov.